Document:

Exhibit 10.7

 

Form of Joinder
to Share Purchase Agreement

 

This Joinder Agreement
(this “Joinder Agreement”) is made as of the date written below by [                ] (the “Joining Party”)
in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment
Agreement”) by and among Enzymotec Ltd. and investors named therein, as the same may be amended from time to time. Capitalized
terms used herein, but not defined, shall have the meaning ascribed to such terms in the Investment Agreement.

 

Whereas,
the Company confirmed to the Joining Party that, pursuant to Section 4.2.1(vi) of Investment Agreement, the Company's has obtained
(or is deemed to have obtained) the irrevocable waiver by all applicable shareholders of the Company and by any other applicable
third party, with respect to any preemptive rights, rights of first refusal, anti-dilution rights, or similar rights such shareholder
or third party may have in connection with the joining of the Joining Party to the Investment Agreement and the issuance to the
Joining Party of the shares, the Warrants and the shares underlying the Warrant, all as set forth in the Investment Agreement and
in this Joinder Agreement.

 

Now,
Therefore, the Joining Party hereby acknowledges,
agrees and confirms that, by its execution of this Joinder Agreement, the Joining Party shall be deemed to be a party to the Investment
Agreement as of the date hereof and shall have all of the rights and obligations of an “Investor” there under as if
it had executed the Investment Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by,
all of the terms, provisions and conditions contained in the Investment Agreement and any other document contemplated thereby.

 

Subject to the terms
and conditions set forth in the Investment Agreement, the Company shall:

 

		(1)	issue and allot to the Joining Party, on the dates set forth in this
section below, [      ] ([       ]) of the Company's Preferred B2 Shares, nominal
value NIS 0.01 each (the "Shares"), at a price per Preferred B Share of US$ 363.30, and in consideration for an
aggregate purchase price of US$ [      ] (the "Investment Amount"), which will be transferred to the Company
as follows: (i) 50% out of the Investment Amount, payable in consideration for [      ] ([      ]) Shares to be issued on the
date hereof – upon signing of this Joinder Agreement, subject to the fulfillment of the terms and conditions set forth in
Section 4.4 of the Investment Agreement; and (ii) the remaining 50% out of the Investment Amount (the "Additional Amount"),
payable in consideration for the remaining [      ] ([      ]) Shares to be issued on the date the Additional Amount is actually
transferred to the Company – in accordance with the provisions of Section 1.3.2 of the Investment Agreement but in any event,
not later than December 31, 2012. For the avoidance of doubt, in the event that the Joining
Party does not transfer to the Company (on such dates set forth in Section 1.3.2 of the Investment Agreement) the Additional Amount
in full, then the number of Shares actually issued on such dates may be correspondingly reduced to reflect the actual portion out
of the Additional Amount transferred to the Company. 

 

		(2)	Issue to the Joining Party, on the date hereof, a Warrant (as defined in the SPA) to purchase [
     ] ([      ]) Shares, at a price per Share of US$ 363.30. Upon receipt by the Company of any portion of the Additional Amount,
it shall issue to the Joining Party an additional Warrant covering 20% of the additional portion of the Additional Amount so transferred,
in accordance with Sections 3.1 and 4.4.6 of the Investment Agreement (up to Warrants to purchase a maximum of additional [
     ] ([      ])).

 

[Signature Page to
Follow]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the undersigned has executed this Joinder Agreement as of the date written below.

 

Date: January ____, 2012

 

	 	 
	 	 
	 	By:	 
	 	Title:	 

	 	Address:	 

 

Acknowledged and Agreed:

 

	 	 
	Enzymotec Ltd.	 
	 	 
	By: Oren Bryan	 
	 	 
	Title: CFO	 
	 	 
	Date: January ____, 2012Exhibit 10.8

 

AMENDMENT & JOINDER TO

SHARE PURCHASE AGREEMENT

 

This Amendment
& Joinder Agreement (this “Joinder Agreement”) to the Share Purchase Agreement dated September 27,
2011, which is attached hereto as Exhibit A (the “SPA”), is made and entered into on March
8, 2012 by and among: (i) Enzymotec Ltd., an Israeli company (the "Company"), (ii) Vintage
Venture Partners III (Cayman) L.P. and Vintage Venture Partners III (Israel) L.P. (together, "Vintage"), (iii)
TPY Capital SA, a  Luxembourg corporation ("TPY", and together with Vintage, the “Joining
Parties”), and (iv) the Investors listed in Exhibit B attached hereto, constituting the
Investors who provided at least 90% of the Investment Amount under the SPA (the "Investors"), which
investors include, among others, the remaining entities of Vintage not participating in the transactions contemplated under
this Joinder Agreement.

 

All capitalized terms
used but not otherwise defined herein shall have the meaning ascribed to such terms in the SPA.

 

Whereas,
the Company confirmed to the Joining Parties that, pursuant to Section 4.2.1(vi) of SPA, that the Company's has obtained the irrevocable
waiver by all applicable shareholders of the Company and by any other applicable third party, with respect to any preemptive rights,
rights of first refusal, anti-dilution rights, or similar rights such shareholder or third party may have in connection with the
joining of the Joining Parties to the SPA and the issuance to the Joining Parties of Preferred B2 Shares, the Warrants and the
Preferred B2 Shares underlying the Warrant, all as set forth in the SPA and in this Joinder Agreement.

 

Now,
Therefore, the parties agree as follows:

 

1.        Each of the
Joining Parties hereby acknowledges, agrees and confirms that, by its execution of this Joinder Agreement, such Joining Party shall
be deemed to be a party to the SPA as of the date hereof and shall have all of the rights and obligations of an “Investor”
there under as if it had executed the SPA. Each of the Joining Parties hereby ratifies, as of the date hereof, and agrees to be
bound by, all of the terms, provisions and conditions contained in the SPA and any other document contemplated thereby.

 

2.        TPY's
Investment. 

 

2.1        Upon
signing hereof, the Company will authorize in principle the issuance and allotment to TPY, on the dates set forth in this section
below, of 5,505 Preferred B2 Shares, nominal value NIS 0.01 each ("Preferred B2 Shares"), at a price per
Preferred B2 Share of US$ 363.30 (the "PPS"), and in consideration for an aggregate purchase price of US$ 2,000,000
(the "TPY Investment Amount"), which will be transferred to the Company as follows: (i) 50% out of the Investment
Amount ("TPY Initial Installment"), payable in consideration for 2,752 Preferred B2 Shares to be issued on the
date of transfer of such installment, which is not later than March 29, 2012; and (ii) the remaining 50% out of the TPY Investment
Amount (the "TPY Additional Amount"), payable in consideration for the remaining 2,753 Preferred B2 Shares to
be issued on the date the Additional Amount is actually transferred to the Company – in accordance with the provisions of
Section 1.3.2 of the SPA but in any event, not later than December 31, 2012. For the avoidance
of doubt, in the event that TPY does not transfer to the Company (on such dates set forth in Section 1.3.2 of the SPA) the TPY
Additional Amount in full, then the number of Preferred B2 Shares actually issued on such dates may be correspondingly reduced
to reflect the actual portion out of the TPY Additional Amount transferred to the Company.

 

2.2        The Company hereby
grants TPY an option (the "Option"), exercisable at any time from the period commencing on the date hereof and
expiring on December 31, 2012 (the “Exercise Period”), to increase its investment in the Company and purchase,
in consideration for an additional amount of US$ 1,200,000, an additional number of 3,303 Preferred B2 Shares, each at the PPS.

 

    	 

    	 

    

 

3.        Vintage's
Investment.

 

3.1        Vintage
Venture Partners III (Cayman) L.P. ("Vintage Cayman") - Upon signing hereof, the Company will authorize in
principle the issuance and allotment to the aforesaid entity of Vintage, on the dates set forth in this section below, of 985
Preferred B2 Shares, nominal value NIS 0.01 each ("Preferred B2 Shares"), at a price per Preferred B2 Share of
US$ 363.30 (the "PPS"), and in consideration for an aggregate purchase price of US$ 358,000 (the "Vintage
Cayman Investment Amount"), which will be transferred to the Company as follows: (i) 50% out of the Vintage Cayman Investment
Amount ("Vintage Cayman Initial Installment"), payable in consideration for 492 Preferred B2 Shares to be issued
on the date of transfer of such installment, which is not later than March 29, 2012; and (ii) the remaining 50% out of the Vintage
Cayman Investment Amount (the "Vintage Cayman Additional Amount"), payable in consideration for the remaining
493 Preferred B2 Shares to be issued on the date the Vintage Cayman Additional Amount is actually transferred to the Company –
in accordance with the provisions of Section 1.3.2 of the SPA but in any event, not later than December 31, 2012.

 

3.2        Vintage Venture
Partners III (Israel) L.P. ("Vintage Israel") - Upon signing hereof, the Company will authorize in principle
the issuance and allotment to the aforesaid entity of Vintage, on the dates set forth in this section below, of 391 Preferred
B2 Shares, nominal value NIS 0.01 each ("Preferred B2 Shares"), at a price per Preferred B2 Share of US$ 363.30
(the "PPS"), and in consideration for an aggregate purchase price of US$ 142,000 (the "Vintage
Israel Investment Amount"), which will be transferred to the Company as follows: (i) 50% out of the Vintage Israel Investment
Amount ("Vintage Israel Initial Installment"), payable in consideration for 195 Preferred B2 Shares to be issued
on the date of transfer of such installment, which is not later than March 29, 2012; and (ii) the remaining 50% out of the Vintage
Israel Investment Amount (the "Vintage Israel Additional Amount"), payable in consideration for the remaining
196 Preferred B2 Shares to be issued on the date the Vintage Israel Additional Amount is actually transferred to the Company –
in accordance with the provisions of Section 1.3.2 of the SPA but in any event, not later than December 31, 2012.

 

3.3        For the avoidance
of doubt, in the event that any of the aforesaid entities of Vintage does not transfer to the Company (on such dates set forth
in Section 1.3.2 of the SPA) the Vintage Cayman Additional Amount or the Vintage Israel Additional Amount, as the case may be,
in full, then the number of Preferred B2 Shares actually issued on such dates may be correspondingly reduced to reflect the actual
portion out of the Vintage Cayman Additional Amount or the Vintage Israel Additional Amount, as the case may be transferred to
the Company.

 

4.        Issuance
of Warrants.

 

4.1        TPY
- The Company will issue to TPY, upon receipt of TPY Initial Installment, a Warrant (as defined in the SPA) to purchase up to 550
Preferred B2 Shares, at the PPS. Upon receipt by the Company of any portion of the TPY Additional Amount, it shall issue to TPY
an additional Warrant covering 20% of the additional portion of the TPY Additional Amount so transferred, in accordance with Sections
3.1 and 4.4.6 of the SPA (up to Warrants to purchase a maximum number of either: (i) 1,101 Preferred B2 Shares in case the Option
is not exercised by TPY, or (ii) 1,762 Preferred B2 Shares in case the Option is exercised by TPY. Each of the aforesaid
maximum number of additional shares includes the initial 550 Preferred B2 Shares referred to above).

 

4.2        Vintage
Cayman – The Company will issue to Vintage Cayman, upon receipt of the Vintage Cayman Initial Installment, a Warrant
to purchase up to 98 Preferred B2 Shares, at the PPS. Upon receipt by the Company of any portion of the Vintage Cayman Additional
Amount, it shall issue to Vintage Cayman an additional Warrant covering 20% of the additional portion of the Vintage Cayman Additional
Amount so transferred, in accordance with Sections 3.1 and 4.4.6 of the SPA (up to Warrants to purchase a maximum of additional
197 Preferred B2 Shares, which number includes the initial 98 Preferred B2 Shares referred to above).

 

    	 

    	 

    

 

4.3        Vintage
Israel - The Company will issue to Vintage Israel, upon receipt of the Vintage Israel Initial Installment, a Warrant to purchase
up to 39 Preferred B2 Shares, at the PPS. Upon receipt by the Company of any portion of the Vintage Israel Additional Amount, it
shall issue to Vintage Israel an additional Warrant covering 20% of the additional portion of the Vintage Israel Additional Amount
so transferred, in accordance with Sections 3.1 and 4.4.6 of the SPA (up to Warrants to purchase a maximum of additional 78 Preferred
B2 Shares, which number includes the initial 39 Preferred B2 Shares referred to above).

 

5.        Section 4.3
of the SPA is hereby amended to state that the deferred Closing shall be extended until December 31, 2012, and shall include the
Option granted hereunder to TPY as part of the Additional Investment Amount.

 

6.        The amendments
made herein are affected in accordance with the provisions of Section 10.6 of the SPA, through the execution of this Joinder Agreement
by the Investors who provided at least 90% of the Investment Amount under the SPA.

 

7.        It is hereby
clarified that, except as specifically amended by the parties in this Joinder Agreement, all the terms of the SPA will remain in
full force and effect and bind the parties (and such other signatories thereof) without any change.

 

8.        Without limiting
the generality of the foregoing, the term “SPA” as used in the Agreement will be deemed to be the SPA as amended by
this Joinder Agreement.

 

[Signature Page to Follow]

 

    	 

    	 

    

 

[Signature Page – Amendment
& Joinder to SPA – Enzymotec Ltd.]

 

IN WITNESS WHEREOF,
the undersigned has executed this Amendment and Joinder Agreement as of the date written below.

 

	THE COMPANY:	 
	 	 
	/s/ Oren Bryan	 
	Enzymotec Ltd.	 

 

By: Oren Bryan

 

Title: CFO

 

	THE JOINING PARTIES:	 
	 	 
	/s/ Dekel Persi         /s/ Jacques Taché	 
	TPY Capital SA	 
	 	 
	By:	Dekel Persi            Jacques Taché	 
	 	 
	Title:	Director              Director	 

 

	/s/ Alan Feld              /s/ Hagai Goldhirsh	 	/s/ Alan Feld              /s/ Hagai Goldhirsh
	Vintage Venture Partners III (Cayman) L.P.	 	Vintage Venture Partners III (Israel) L.P.
	 	 	 
	By: 	Alan Feld              Hagai
Goldhirsh	 	By:	 Alan Feld              Hagai
Goldhirsh
	 	 	 
	Title:	 President              CFO	 	Title:	 President              CFO

 

    	 

    	 

    

 

[Signature Page – Amendment
& Joinder to SPA – Enzymotec Ltd.]

 

IN WITNESS WHEREOF,
the undersigned has executed this Amendment and Joinder Agreement as of the date written below.

 

THE INVESTORS:

 

	/s/ Samuel Eshed          /s/
    Bilha Sova	 	/s/ Zwi Vroman                /s/
    Belzer Nir
	Galam Ltd.	 	Millennium II Materials Technology Fund L.P.
			 	 
	By:	Samueal Eshed        Bilha
    Sova	 	By:	Zwi Vroman               Belzer
    Nir
	Title:	 	 	Title: 	 

 

	/s/ Yoav Doppelt	 	/s/ Ignacio Aranguren-Trellez
	Ofer Hi-Tech Investments Ltd.	 	Arancia International, Inc.
	 	 	 
	By: 	Yoav Doppelt	 	By:	Ignacio Aranguren-Trellez
	Title:	 	 	Title:	President

 

	/s/ Alan Feld	 	/s/ Belzer Nir
	Vintage Venture Partners, L.P.	 	M-4 Management L.P.
	 	 	 
	By:	Alan Feld	 	By:	Belzer Nir
	Title:	 	 	Title:	 

 

	/s/ Alan Feld	 	/s/ Alan Feld
	Vintage Venture Partners (Parallel), L.P.	 	Vintage Venture Partners (Israel), L.P.
	 	 	 
	By:	Alan Feld	 	By:	Alan Feld
	Title:	 	 	Title:	 

 

	/s/ Natalia Sutugina           /s/ Viviane Graffé	 	/s/ Tova Posner Henkin           /s/ Ofer Borovsky
	BIP Venture Partners SA, SICAR	 	Plasson Ltd.
	 	 	 
	By:	Natalia Sutugina           Viviane Graffé	 	By:	Tova Posner Henkin           Ofer Borovsky
	Title:	Investment Manager     CFAO	 	Title:	CEO                                    Joint CFO

 

    	 

    	 

    

 

[Signature Page – Amendment
& Joinder to SPA – Enzymotec Ltd.]

 

IN WITNESS WHEREOF,
the undersigned has executed this Amendment and Joinder Agreement as of the date written below.

 

THE INVESTORS:

 

	/s/ Shmuel
    Shilo           /s/ Dror Glass	 	/s/ Shmuel
    Shilo           /s/ Dror Glass
	Israel Secondary Fund (Israel) L.P.	 	Israel Secondary Investments  (BVI) L.P.
			 	 
	By:	Shmuel Shilo          
    Dror Glass	 	By:	 Shmuel Shilo
              Dror Glass
	Title:	Managing Partners	 	Title:	 Managing Partners
	 	 	 
	/s/ Leon Recanati	 	 
	Glenrock Israel Ltd.	 	 
	 	 	 
	By:	Leon Recanati	 	 
	Title:	Chairman and CEO	 	 

 

    	 

    	 

    

 

Exhibit A

 

SPA

 

    	 

    	 

    

 

Exhibit B

 

List of Investors

 

		1.	Galam Ltd.

		2.	Ofer Hi-Tech Investments Ltd.

		3.	Millennium II Materials Technology Fund L.P.

		4.	Arancia International, Inc.

		5.	M-4 Management L.P.

		6.	Vintage Venture Partners, L.P.

		7.	Vintage Venture Partners (Israel), L.P.

		8.	Vintage Venture Partners (Parallel), L.P.

		9.	BIP Venture Partners SA, SICAR

		10.	Plasson Ltd.

		11.	Israel Secondary Fund (Israel) L.P.

		12.	Israel Secondary Investments (BVI) L.P

		13.	Glenrock Israel Ltd.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]